All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Patient Square Capital bankrolled a new portfolio company, Elevage Medical Technologies, with $300 million to provide capital and strategic expertise to promising medical device companies. Evan Melrose, founding managing director of Spindletop Capital and a practicing family medicine physician, will lead Elevage.
Med-tech companies are facing a new reality of high interest rates, inflation, bank failures, and geopolitical turmoil that are impacting financing and M&A opportunities. To secure finance and attract partnership deals they must keep their product simple, focus on proof of concept and ensure that it has quality, delegates at the LSX World Congress in London heard during a panel presentation.
Pattern Bioscience Inc. reeled in $28.7 million in a series C financing led by Illumina Ventures and Omnimed Capital. The money will be used to complete development of its rapid phenotypic test platform for infectious diseases, conduct clinical validation studies and submit the platform and Pattern’s initial test, for pneumonia, for U.S. FDA review.
Avertix Medical Inc. signed a definitive merger agreement with Bios Acquisition Corp., a special purpose acquisition company (SPAC), in a deal that will take the company public on the Nasdaq. The deal will establish the combined entity, which will continue under the Avertix name and trade as AVRT, with an estimated enterprise value of $195 million. The transaction is expected to close in the second half of the year.
Buoyed by the progress it has made with its lead integrin therapy for moderate to severe ulcerative colitis, MORF-057, which significantly reduced disease activity in a phase IIa trial, Morphic Therapeutic Inc. is raising $240 million in a public offering to further advance the candidate through the clinic.
The IPO market in Europe is firmly shut and not a single company went public in the first quarter of 2023. The impact of this is trickling down to limit access to venture capital for biotechs.